Prostate cancer is the second-leading cause of cancer death in American men.About 1 in 8 men will be diagnosed with prostate ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

Thousands of men battling prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

A life-extending prostate cancer drug is to be made available to thousands of men in England in a matter of weeks, after a campaign by a patient and a charity. Abiraterone has been provided on the NHS ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...